Alnylam Pharmaceuticals ALNY AMVUTTRA — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alnylam Pharmaceuticals's amvuttra — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alnylam Pharmaceuticals's AMVUTTRA — total revenues?
- Alnylam Pharmaceuticals (ALNY) reported AMVUTTRA — total revenues of $1.01B in Q2 2026.
- How has Alnylam Pharmaceuticals's AMVUTTRA — total revenues changed year-over-year?
- Alnylam Pharmaceuticals's AMVUTTRA — total revenues increased by 105.7% year-over-year, from $491.95M to $1.01B.
- What is the long-term trend for Alnylam Pharmaceuticals's AMVUTTRA — total revenues?
- Over 3 years (2022 to 2025), Alnylam Pharmaceuticals's AMVUTTRA — total revenues has grown at a 191.1% compound annual growth rate (CAGR), from $93.8M to $2.31B.
- What does AMVUTTRA — total revenues mean?
- This metric represents the total gross revenue generated from the sales of a specific therapeutic product within the company's portfolio. It reflects the market adoption, commercial success, and patient demand for this particular RNA interference treatment. Tracking this revenue stream is essential for evaluating the product's contribution to overall top-line growth and its lifecycle performance in the competitive pharmaceutical landscape.